Mark Anthony Michaels

US Patent:

8034770, Oct 11, 2011

Filed:

Jun 3, 2009

Appl. No.:

12/455610

Inventors:

Edward John Belouski - Camarillo CA, US
Murielle Marie Ellison - Thousand Oaks CA, US
Agnes Eva Hamburger - Newbury Park CA, US
Randy Ira Hecht - Thousand Oaks CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Jeonghoon Sun - Thousand Oaks CA, US
Jing Xu - Thousand Oaks CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 38/18
C07K 14/50

US Classification:

514 91, 530350, 530399

Abstract:

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

US Patent:

8188040, May 29, 2012

Filed:

May 4, 2010

Appl. No.:

12/773266

Inventors:

Edward John Belouski - Camarillo CA, US
Murielle Marie Ellison - Thousand Oaks CA, US
Agnes Eva Hamburger - Thousand Oaks CA, US
Randy Ira Hecht - Thousand Oaks CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Jeonghoon Sun - Thousand Oaks CA, US
Jing Xu - Thousand Oaks CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 38/18
C07K 14/50
C12N 1/21
C12N 5/10
C12N 15/12
C12N 15/63

US Classification:

514 91, 530350, 530399, 536 235, 4353201, 435325, 435243

Abstract:

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

US Patent:

8361963, Jan 29, 2013

Filed:

Dec 16, 2011

Appl. No.:

13/328028

Inventors:

Edward John Belouski - Camarillo CA, US
Murielle Marie Ellison - Thousand Oaks CA, US
Agnes Eva Hamburger - Newbury Park CA, US
Randy Ira Hecht - Thousand Oaks CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Jeonghoon Sun - Thousand Oaks CA, US
Jing Xu - Thousand Oaks CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 38/18
C07K 14/50

US Classification:

514 91, 530350, 530399

Abstract:

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

US Patent:

8410043, Apr 2, 2013

Filed:

Nov 25, 2009

Appl. No.:

12/626375

Inventors:

Jeonghoon Sun - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Thomas C. Boone - Newbury Park CA, US
Rohini Deshpande - Camarillo CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Hq Han - Thousand Oaks CA, US

Assignee:

Atara Biotherapeutics, Inc. - Brisbane CA

International Classification:

A61K 38/00
A61K 38/18

US Classification:

514 11, 514 69, 514 76

Abstract:

The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

US Patent:

8410051, Apr 2, 2013

Filed:

Aug 2, 2011

Appl. No.:

13/196544

Inventors:

Edward John Belouski - Camarillo CA, US
Murielle Marie Ellison - Thousand Oaks CA, US
Agnes Eva Hamburger - Newbury Park CA, US
Randy Ira Hecht - Thousand Oaks CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Jeonghoon Sun - Thousand Oaks CA, US
Jing Xu - Thousand Oaks CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 38/18
C07K 14/50
C12N 1/21
C12N 5/10
C12N 15/12
C12N 15/63

US Classification:

514 91, 530350, 530399, 536 235, 4353201, 435325, 435243

Abstract:

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

US Patent:

8618053, Dec 31, 2013

Filed:

May 3, 2012

Appl. No.:

13/463731

Inventors:

Edward John Belouski - Camarillo CA, US
Murielle Marie Ellison - Thousand Oaks CA, US
Agnes Eva Hamburger - Newbury Park CA, US
Randy Ira Hecht - Thousand Oaks CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Jeonghoon Sun - Thousand Oaks CA, US
Jing Xu - Thousand Oaks CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 38/18
A61K 39/395
C07K 14/50
C07K 16/00

US Classification:

514 91, 530399, 4241301

Abstract:

The invention provides a multimer comprising at least a first and a second chain, the first chain comprising the polypeptide of SEQ ID NO:4, wherein the leucine at position 98 is substituted with an arginine; the proline at position 171 is substituted with glycine; and the alanine at position 180 is substituted with glutamic acid; a linker sequence comprising SEQ ID NO:31; and an Fe domain comprising SEQ NO:11; and a second chain comprising the polypeptide of SEQ ID NO:4, wherein the leucine at position 98 is substituted with an arginine; the proline at position 171 is substituted with glycine; and the alanine at position 180 is substituted with glutamic acid; a linker sequence comprising SEQ ID NO:31; and an Fe domain comprising SEQ ID NO:11, nucleic acids encoding the multimer, pharmaceutical compositions comprising the multimer and methods for treating metabolic disorders using such nucleic acids, multimers or pharmaceutical compositions.

US Patent:

8642546, Feb 4, 2014

Filed:

Dec 15, 2011

Appl. No.:

13/327504

Inventors:

Edward John Belouski - Camarillo CA, US
Murielle Marie Ellison - Thousand Oaks CA, US
Agnes Eva Hamburger - Newbury Park CA, US
Randy Ira Hecht - Thousand Oaks CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark Leo Michaels - Encino CA, US
Jeonghoon Sun - Thousand Oaks CA, US
Jing Xu - Thousand Oaks CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 38/18
C07K 14/50
A61K 39/395
C07K 16/00

US Classification:

514 91, 530399, 530350, 5303871

Abstract:

The invention provides nucleic acid molecules encoding FGF21 mutant fusion polypeptides comprising mutations at positions 98, 171, 179, 180 or 181, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

US Patent:

20110195895, Aug 11, 2011

Filed:

Oct 8, 2009

Appl. No.:

13/123205

Inventors:

Kenneth W. Walker - Newbury Park CA, US
Randy I. Hecht - Thousand Oaks CA, US
Edward J. Belousky - Camarillo CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Mark L. Michaels - Encino CA, US
Jing Xu - Thousand Oaks CA, US
Murielle M. Ellison - Thousand Oaks CA, US

Assignee:

Amgen Inc. - Thousand Oak

International Classification:

A61K 38/18
C12N 15/63
C12N 1/00
C07H 21/00
C12P 21/02
C07K 14/50
C08F 8/32
C07K 19/00
A61P 3/10
A61P 3/04
A61P 3/00

US Classification:

514 48, 4353201, 435243, 536 235, 435 691, 530399, 525 541, 530397, 514 91, 514 69

Abstract:

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.